HOME >> BIOLOGY >> NEWS
Resveratrol prolongs lifespan and delays onset of aging-related traits in a short-lived vertebrate

By studying a particularly short-lived fish species, researchers have been able to show that a natural compound previously shown to extend lifespan in non-vertebrate organisms can also do so in at least one vertebrate species. The findings, reported by Alessandro Cellerino of the Scuola Normale Superiore, Pisa, and colleagues, support the potential utility of the compound in human aging research.

The development of drugs able to retard the onset of aging-related diseases and improve quality of life in the elderly is a growing focus of aging research and public health in modern society. But the successful development of drugs aimed at aging-related diseases needs to face the challenge posed by the lifespan of the available animal models--mammalian models for aging are relatively long-lived and aren't as easily studied as shorter-lived species.

Resveratrol is an organic compound naturally present in grapes--and particularly enriched in red wine--and was previously shown to prolong lifespan in non-vertebrate model organisms such as yeast, the worm C. elegans, and the fruit fly Drosophila. However, until now, life-long pharmacological trials were performed in the worm or fly model organisms because of their very small size, very short natural lifespan, and affordable cultivation costs. Laboratory mice, on the other hand, live more than two years and are relatively expensive to maintain, making large-scale, life-long pharmacological trials in mice unaffordable.

Recently, a small fish species with a captive lifespan of only three months was described by Cellerino and colleagues. In the new work, the researchers used this short-lived fish to test the effects of resveratrol on aging-related physiological decay. The researchers added resveratrol to daily fish food and found that this treatment increased longevity and also retarded the onset of aging-related decays in memory and muscular performance.

Resveratrol appears to be the first molecu
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
6-Feb-2006


Page: 1 2

Related biology news :

1. Red wine mist? Resveratrol shows potential effects against COPD, asthma, arthritis
2. Paclitaxel combined with bevacizumab prolongs progression free survival in metastatic breast cancer
3. ECCO 13 - Sunitinib prolongs survival in GIST patients after imatinib mesylate failure
4. Researchers find link between food odors and lifespan in fruit flies
5. Reduced body temperature extends lifespan in study from the Scripps Research Institute
6. Fish evolve a longer lifespan by evolving a longer reproductive period, researchers find
7. MicroRNA gene that regulates lifespan found by Yale scientists
8. New lifespan extension genes found
9. Researchers extend mouse lifespan by protecting against free radicals
10. DDT in mothers linked to developmental delays in children, UC Berkeley study finds
11. Sexual reproduction delays aging in a mammalian species

Post Your Comments:
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
(Date:5/30/2015)... May 30, 2015 CTI BioPharma Corp. (CTI ... business (NYSE: BAX ) today announced data from ... pacritinib for the treatment of myelofibrosis – in a ... of the American Society of Clinical Oncology (ASCO), May ... Pacritinib is an investigational oral multikinase inhibitor with ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
(Date:5/29/2015)... CHAPEL HILL, N.C. , May 29, 2015 ... the medical affairs function into roles involving clinical ... As its responsibilities have grown, Medical Affairs ... the function as a global group. And while ... sometimes find it challenging to identify strong performance ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2
Cached News: